+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Drug Overview: Provenge

  • ID: 4462132
  • Drug Pipelines
  • 13 pages
  • Datamonitor Healthcare
1 of 3
Drug Overview

Provenge (sipuleucel-T; Sanpower Group) is a cellular immunotherapy composed of autologous dendritic cells loaded with the recombinant antigen prostatic acid phosphatase (PAP), which is expressed on approximately 95% of prostate tumor cells. The vaccine is administered alongside a granulocyte-macrophage colony-stimulating factor adjuvant. Upon injection, the PAP-loaded dendritic cells cause activation of T cells, which recognize the target antigen and destroy prostate tumor cells.
Note: Product cover images may vary from those shown
2 of 3
Product Profiles
Provenge: Prostate cancer

List of Figures
Figure 1: Provenge for prostate cancer - SWOT analysis
Figure 2: Drug assessment summary of Provenge for prostate cancer
Figure 3: Drug assessment summary of Provenge for prostate cancer
Figure 4: Provenge sales for prostate cancer in the US, 2017-26

List of Tables
Table 1: Provenge drug profile
Table 2: Provenge pivotal Phase III data in prostate cancer
Table 3: Provenge sales for prostate cancer in the US ($m), 2017-26
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4462132
Adroll
adroll